Despite Headwinds On Glivec, Novartis Gears Up To Bring Tasigna To India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - For many years Swiss pharmaceutical giant Novartis voiced reservations about certain provisions of the Indian patent laws and data exclusivity issues, but the maker of Glivec (imatinib) looks set to introduce its next-line therapy for chronic myeloid leukemia Tasigna (nilotinib) into the Indian market
You may also be interested in...
Tasigna Beats Sprycel To First-Line CML Punch
Now that Novartis' Tasigna (nilotinib) has been approved by FDA for the treatment of first-line chronic myeloid leukemia, the race has officially begun for two second-generation BCR-ABL kinase inhibitors to supplant the venerable market-leader, Novartis' Gleevec (imatinib)
Indian Pharmaceutical Alliance Defends Section 3(d) Of Patents Act, Says Statute Not Against Incremental Innovations
MUMBAI - The Indian Pharmaceutical Alliance - an influential lobbying group that represents 15 leading Indian drug makers - has stridently opposed a 2009 report published by the U.S.-India Business Council that called for certain changes in the country's Patents Act
Novartis Designs “Arogya Parivar” To Reach Real India In Its Rural Centers
MUMBAI - Swiss drug maker Novartis recently launched its ace anti-diabetes drug Galvus in India to take Merck's Januvia head on, but the company's larger focus seems to be shifting fast from the mega cities to the rural market where "real India lives.